- Home
- TOMZ vs CVM Comparison
TOMZ vs CVM Comparison
Compare TOMZ & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | CVM |
|---|---|---|
| Founded | 1979 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 20.4M |
| IPO Year | 2009 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TOMZ | CVM |
|---|---|---|
| Price | $1.55 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 109.1K | ★ 401.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | $264,033.00 |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.50 | $0.89 |
| 52 Week High | $2.12 | $13.48 |
Technical Indicators
Market Signals| Indicator | TOMZ | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 69.76 | 45.13 |
| Support Level | $0.62 | $0.98 |
| Resistance Level | N/A | $1.52 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 64.24 | 28.17 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.